- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
- Interventions
- Anastrozole, Biospecimen Collection, Bone Scan, Chemotherapy, Computed Tomography, Exemestane, Letrozole, Oncotype DX Breast Cancer Assay, Positron Emission Tomography, Ribociclib Succinate
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,978 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 203
- States / cities
- Jonesboro, Arkansas • Auburn, California • Berkeley, California + 169 more
Institution Directory
Clinical trials at NYU Langone Health
Sites in New York, NY
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1135
Shown on this page
12
Local recruiting
615
Top conditions
6
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 1–12 of 1,135 matching trials with a site at NYU Langone Health, New York, NY.
Live ClinicalTrials.gov results.
Top conditions
Top therapies
Top lead sponsors
Live official records
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544
Status at this site: Recruiting
- Conditions
- Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor
- Interventions
- TNG456, abemaciclib
- Drug
- Lead sponsor
- Tango Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Irvine, California • Los Angeles, California + 11 more
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04284774
Site status not listed — check the official record
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
- Interventions
- Tipifarnib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 171
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069
Status at this site: Not yet recruiting
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
- Interventions
- LY4052031, Pembrolizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 22
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 15 more
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152
Status at this site: Recruiting
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma
- Interventions
- Atebimetinib, GnP, mGnP
- Drug
- Lead sponsor
- Immuneering Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 45
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Duarte, California + 39 more
- Conditions
- Heart Failure, NYHA Class III Heart Failure, NYHA Class II Heart Failure
- Interventions
- IVC Sensor
- Device
- Lead sponsor
- Foundry Innovation & Research 1, Limited (FIRE1)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 25
- States / cities
- Chula Vista, California • Sacramento, California • Jacksonville, Florida + 19 more
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT05271409
Site status not listed — check the official record
- Conditions
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
- Interventions
- Satralizumab, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more
- Conditions
- Solid Tumors, Hematologic Malignancies
- Interventions
- Pembrolizumab, Standard of Care (SOC), Lenvatinib, Olaparib, MK-4280, MK-4280A, Pembrolizumab (+) Berahyaluronidase alfa
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2043
- U.S. locations
- 65
- States / cities
- Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373
Status at this site: Active, not recruiting
- Conditions
- VEXAS, VEXAS Syndrome
- Interventions
- Pacritinib, Placebo
- Drug
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • Rochester, Minnesota + 6 more
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
NCT04674969
Status at this site: Recruiting
- Conditions
- Peripheral Vascular Diseases
- Interventions
- Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 53
- States / cities
- Jonesboro, Arkansas • Los Angeles, California • Sacramento, California + 42 more
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Interventions
- Paradise Ultrasound Renal Denervation Treatment
- Device
- Lead sponsor
- ReCor Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 46
- States / cities
- Long Beach, California • Los Angeles, California • Sacramento, California + 39 more
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637
Site status not listed — check the official record
- Conditions
- Breast Cancer
- Interventions
- PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 216
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 132 more
About this NYU Langone Health institution page
- What this page lists
- ClinicalTrials.gov records that list NYU Langone Health in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
- Site status
- A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages, browse by condition, or browse by U.S. city.